| 1 |
Heslop HE. How I treat EBV lymphoproliferation[J]. Blood, 2009, 114(19): 4002-4008.
|
| 2 |
Martinez OM, Krams SM. The immune response to Epstein Barr virus and implications for posttransplant lymphoproliferative disorder[J]. Transplantation, 2017, 101(9): 2009-2016.
|
| 3 |
Abbas F, El Kossi M, Shaheen IS, et al. Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches[J]. World J Transplant, 2020, 10(2): 29-46.
|
| 4 |
Krams SM, Martinez OM. Epstein-Barr virus, rapamycin, and host immune responses[J]. Curr Opin Organ Transplant, 2008, 13(6): 563-568.
|
| 5 |
Vereide DT, Sugden B. Lymphomas differ in their dependence on Epstein-Barr virus[J]. Blood, 2011, 117(6): 1977-1985.
|
| 6 |
Burns DM, Tierney R, Shannon-Lowe C, et al. Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event[J]. Blood, 2015, 126(25): 2665-2675.
|
| 7 |
Ferreiro JF, Morscio J, Dierickx D, et al. EBV-positive and EBV-negative posttransplant diffuse large B cell lymphomas have distinct genomic and transcriptomic features[J]. Am J Transplant, 2016, 16(2): 414-425.
|
| 8 |
Courville EL, Yohe S, Chou D, et al. EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations[J]. Mod Pathol, 2016, 29(10): 1200-1211.
|
| 9 |
Dierickx D, Tousseyn T, Gheysens O. How I treat posttransplant lymphoproliferative disorders[J]. Blood, 2015, 126(20): 2274-2283.
|
| 10 |
Weisenburger DD, Gross TG. Post-transplant lymphoproliferative disorder: a heterogeneous conundrum[J]. Br J Haematol, 2017, 179(5): 854-856.
|
| 11 |
Doak PB, Montgomerie JZ, North JD, et al. Reticulum cell sarcoma after renal homotransplantation and azathioprine and prednisone therapy[J]．Br Med J, 1968, 4(5633): 746-748.
|
| 12 |
Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report[J]. Am J Transplant, 2004, 4(2): 222-230.
|
| 13 |
Dierickx D, Tousseyn T, Sagaert X, et al. Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors[J]. Leuk Lymphoma, 2013, 54(11): 2433-2440.
|
| 14 |
Zaffiri L, Long A, Neely ML, et al. Incidence and outcome of post-transplant lymphoproliferative disorders in lung transplant patients: Analysis of ISHLT Registry[J]. J Heart Lung Transplant, 2020, 39(10): 1089-1099.
|
| 15 |
Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation[J]. Crit Rev Oncol Hematol, 2005, 56(1): 155-167.
|
| 16 |
Cherikh WS, Kauffman HM, Mcbride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation[J]. Transplantation, 2003, 76(9): 1289-1293.
|
| 17 |
Opelz G, Daniel V, Naujokat C, et al. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma[J]. Transplantation, 2009, 88(8): 962-967.
|
| 18 |
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390.
|
| 19 |
Sandlund JT, Guillerman RP, Perkins SL, et al. International pediatric non-hodgkin lymphoma response criteria[J]. J Clin Oncol, 2015, 33(18): 2106-2111.
|
| 20 |
Panagiotidis E, Quigley AM, Pencharz D, et al. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis of post-transplant lymphoproliferative disorder[J]. Leuk Lymphoma, 2014, 55(3): 515-519.
|
| 21 |
Allen UD, Preiksaitis JK. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9): e13652.
|
| 22 |
Romero S, Montoro J, Guinot M, et al. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation[J]. Leuk Lymphoma, 2019, 60(1): 142-150.
|
| 23 |
刘占祥. 移植后淋巴细胞增殖性疾病诊断进展与治疗规范[J]. 白血病·淋巴瘤，2017, 26(8): 502-505.
|
| 24 |
Destefano CB, Desai SH, Shenoy AG, et al. Management of post-transplant lymphoproliferative disorders[J]. Br J Haematol, 2018, 182(3): 330-343.
|
| 25 |
San-Juan R, Manuel O, Hirsch HH, et al. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey[J]. Clin Microbiol Infect, 2015, 21(6): 601-604.
|
| 26 |
Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder (★) [J]. Am J Transplant, 2011, 11(2): 336-347.
|
| 27 |
Parker A, Bowles K, Bradley JA, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients-BCSH and BTS Guidelines[J]. Br J Haematol, 2010, 149(5): 693-705.
|
| 28 |
Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults[J]. N Engl J Med, 2018, 378(6): 549-562.
|
| 29 |
Doubrovina E, Oflaz-Sozmen B, Prockop SE, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation[J]. Blood, 2012, 119(11): 2644-2656.
|
| 30 |
Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients[J]. Blood, 2010, 115(5): 925-935.
|
| 31 |
Prockop SE, Vatsayan A. Epstein-Barr virus lymphoproliferative disease after solid organ transplantation[J]. Cytotherapy, 2017, 19(11): 1270-1283.
|
| 32 |
Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial[J]. Blood, 2007, 110(4): 1123-1131.
|
| 33 |
Chiou FK, Beath SV, Wilkie GM, et al. Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children[J]. Pediatr Transplant, 2018, 22(2): e13133.
|
| 34 |
Dharnidharka VR, Mohanakumar T. New approaches to treating B-cell cancers induced by Epstein-Barr virus[J]. N Engl J Med, 2015, 372(6): 569-571.
|
| 35 |
Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study[J]. Blood, 2006, 107(8): 3053-3057.
|
| 36 |
Choquet S, Oertel S, Leblond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution[J]. Ann Hematol, 2007, 86(8): 599-607.
|
| 37 |
Choquet S, Trappe R, Leblond V, et al. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation[J]. Haematologica, 2007, 92(2): 273-274.
|
| 38 |
Trappe RU, Dierickx D, Zimmermann H, et al. Response to rituximab induction is a predictive marker in B-Cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase Ⅱtrial[J]. J Clin Oncol, 2017, 35(5): 536-543.
|
| 39 |
Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial[J]. Lancet Oncol, 2012, 13(2): 196-206.
|
| 40 |
Odumade OA, Hogquist KA, Balfour HJ. Progress and problems in understanding and managing primary Epstein-Barr virus infections[J]. Clin Microbiol Rev, 2011, 24(1): 193-209.
|
| 41 |
Aldabbagh MA, Gitman MR, Kumar D, et al. The role of antiviral prophylaxis for the prevention of Epstein-Barr virus-associated posttransplant lymphoproliferative disease in solid organ transplant recipients: a systematic review[J]. Am J Transplant, 2017, 17(3): 770-781.
|
| 42 |
Perrine SP, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies[J]. Blood, 2007, 109(6): 2571-2578.
|
| 43 |
Shyamasundar S, Dheen ST, Bay BH. Histone modifications as molecular targets in nasopharyngeal cancer[J]. Curr Med Chem, 2016, 23(2): 186-197.
|
| 44 |
Cavaliere R, Petroni G, Lopes MB, et al. Primary central nervous system post-transplantation lymphoproliferative disorder: an international primary central nervous system lymphoma collaborative group report[J]. Cancer, 2010, 116(4): 863-870.
|
| 45 |
Evens AM, Choquet S, Kroll-Desrosiers AR, et al. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era[J]. Am J Transplant, 2013, 13(6): 1512-1522.
|
| 46 |
Wu M, Sun J, Zhang Y, et al. Intrathecal rituximab for EBV-associated post-transplant lymphoproliferative disorder with central nervous system involvement unresponsive to intravenous rituximab-based treatments: a prospective study[J]. Bone Marrow Transplant, 2016, 51(3): 456-458.
|
| 47 |
Läubli H, Tzankov A, Juskevicius D, et al. Lenalidomide monotherapy leads to a complete remission in refractory B-cell post-transplant lymphoproliferative disorder[J]. Leuk Lymphoma, 2016, 57(4): 945-948.
|